Original ArticlesRivastigmine Treatment for the Prevention of Electroconvulsive Therapy–Induced Memory Deficits in Patients With SchizophreniaStryjer, Rafael MD*†; Ophir, Dana MD*; Bar, Faina MD*†; Spivak, Baruch MD*†; Weizman, Abraham MD†‡; Strous, Rael D. MD*†Author Information *Beer Yaakov-Ness Ziona Mental Health Center, Beer Yaakov; †Sackler Faculty of Medicine, Tel-Aviv, University, Tel Aviv; and ‡Research Unit, Geha Mental Health Center, Petach-Tikva, Israel. Rafael Stryjer and Dana Ophir contributed equally to this work. Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare. Address correspondence and reprint requests to Rafael Stryjer, MD, Beer Yaakov Mental Health Center, PO Box 1, Beer Yaakov 70350, Israel; E-mail: email@example.com Clinical Neuropharmacology: July/August 2012 - Volume 35 - Issue 4 - p 161-164 doi: 10.1097/WNF.0b013e31825e7945 Buy Metrics Abstract Electroconvulsive therapy (ECT) is an effective strategy in some treatment-resistant patients with schizophrenia. However, ECT is associated with cognitive adverse effects, most notably, memory loss. This study examined the effects of rivastigmine, a selective central nervous system acetylcholinesterase inhibitor, with benefits on cognition in Alzheimer disease, on memory performance in patients with schizophrenia treated with ECT. Thirty inpatients with Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision schizophrenia treated with ECT were coadministered rivastigmine (3–4.5 mg/d) or placebo in a prospective, randomized, double-blind, placebo-controlled trial (maximum period of 4 weeks). Over the ECT course, scores on the cognitive subscale of the Alzheimer’s Disease Assessment in subjects receiving placebo showed no significant change, whereas subjects receiving rivastigmine displayed decreased cognitive subscale of the Alzheimer’s Disease Assessment scores, indicating cognitive improvement (P < 0.05). Findings suggest possible involvement of the acetylcholinergic system in mediation of cognitive deficits after ECT and indicate possible beneficial effects of rivastigmine coadministration in minimizing some of these ECT-induced cognitive impairments. © 2012 Lippincott Williams & Wilkins, Inc.